Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension

European Respiratory Journal

Volumn 29, Issue 5, 2007, Pages 937-943

  Perros, F ^a,b   Dorfmuller P ^a,b   Souza, R ^a   Durand Gasselin, I ^b   Godot, V ^b   Capel, F ^b   Adnot, S ^c   Eddahibi, S ^c   Mazmanian, M ^d   Fadel, E ^d   Herve P ^d   Simonneau, G ^a   Emilie, D ^b   Humbert, Marc ^a,b  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Chemokines; Fractalkine; Proliferation; Pulmonary hypertension; Smooth muscle cell

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; FRACTALKINE; GROWTH FACTOR; MONOCROTALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY RESISTANCE; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; LASER CAPTURE MICRODISSECTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CELL DIVISION; CHEMOKINES, CX3C; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 34248209543     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00104706     Document Type: Article

References (36)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
2. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43: 25S-32S.
3. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 13S-24S.
4. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 40S-47S.
5. Tuder RM, Voelkel NF. Pulmonary hypertension and inflammation. J Lab Clin Med 1998; 132: 16-24.
6. Montani D, Achouh L, Marcelin AG, et al. Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. Eur Respir J 2005; 26: 969-972.
7. Sanchez O, Sitbon O, Jais X, et al. Immunosuppressive therapy in connective tissue diseases associated pulmonary arterial hypertension. Chest 2006; 130: 182-189.
8. Humbert M, Trembath RC. Genetics of pulmonary hypertension: from bench to bedside. Eur Respir J 2002; 20: 741-749.
9. Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 325-334.
10. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11: 554-559.
11. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821.
12. Souza R, Sitbon O, Parent F, Simmoneau G, Humbert M. Long-term imatinib therapy in pulmonary arterial hypertension. Thorax 2006; 61: 736.
13. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412-1413.
14. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: 1628-1631.
15. 3C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 1419-1425.
16. Dorfmuller P, Zarka V, Durand-Gasselin I, et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 534-539.
17. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385: 640-644.
18. Harrison JK, Jiang Y, Chen S, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 1998; 95: 10896-10901.
19. Harrison JK, Jiang Y, Wees EA, et al. Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart. J Leukoc Biol 1999; 66: 937-944.
20. Imaizumi T, Yoshida H, Satoh K. Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb 2004; 11: 15-21.
21. Lucas AD, Chadwick N, Warren BF, et al. The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am J Pathol 2001; 158: 855-866.
22. Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91: 521-530.
23. Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 34-40.
24. Wong BW, Wong D, McManus BM. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 2002; 11: 332-338.
25. Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003; 111: 333-340.
26. Chandrasekar B, Mummidi S, Perla RP, et al. Fractalkine (CX3CL1) stimulated by nuclear factor κB (NF-κB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J 2003; 373: 547-558.
27. Stinger RB, Iacopino VJ, Alter I, Fitzpatrick TM, Rose JC, Kot PA. Catheterization of the pulmonary artery in the closed-chest rat. J Appl Physiol 1981; 51: 1047-1050.
28. Eddahibi S, Fabre V, Boni C, et al. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin. Circ Res 1999; 84: 329-336.
29. Garin A, Tarantino N, Faure S, et al. Two novel fully functional isoforms of CX3CR1 are potent HIV coreceptors. J Immunol 2003; 171: 5305-5312.
30. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108: 1141-1150.
31. Foussat A, Bouchet-Delbos L, Berrebi D, et al. Deregulation of the expression of the fractalkine/fractalkine receptor complex in HIV-1-infected patients. Blood 2001; 98: 1678-1686.
32. Lucas AD, Bursill C, Guzik TJ, Sadowski J, Channon KM, Greaves DR. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 2003; 108: 2498-2504.
33. Meyrick B, Gamble W, Reid L. Development of Crotalaria pulmonary hypertension: hemodynamic and structural study. Am J Physiol 1980; 239: H692-H702.
34. Kimura H, Kasahara Y, Kurosu K, et al. Alleviation of monocrotaline-induced pulmonary hypertension by anti-bodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 1998; 78: 571-581.
35. Moatti D, Faure S, Fumeron F, et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 2001; 97: 1925-1928.
36. McDermott DH, Halcox JP, Schenke WH, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 2001; 89: 401-407.